TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 'Feel High' rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 'Like Drug' rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: LVM/height reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mitral E/A ratio increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting glucose levels change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Validation of the CECDAI scoring system for mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma high-sensitivity C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NeuroQuick (NQT) assessment of small nerve fiber dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BRS function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HRV indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lifetime history of rapid cycling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to mood stabilizers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic infection prevention
Endpoint domain: Adverse events/effects
Primary endpoint: HPV prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of non-PV AF foci in the LA after PVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Elimination of AF foci by focal ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in symptoms of ragweed rhinoconjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ragweed IgE and IgG4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient's global assessment of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankylosing spondylitis disease activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increases in RW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Folic acid concentration in human feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: return of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Costs
Endpoint domain: Resource use
Primary endpoint: reduced marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative consequences of marijuana use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Naming accuracy of graphic symbols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification effectiveness of graphic symbols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gains in knowledge about informed consent
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endotoxin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-of-treatment abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TB recurrence
Endpoint domain: Mortality/survival
Primary endpoint: unfavorable response at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality of the posterior descending artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral vessel diameter reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peripheral attenuation of contrast agent density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver's knowledge of bipolar disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of synechiae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mucosal healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of fractures healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of disease (SAPS-II, SOFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luminal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cry/fuss duration per 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIN2+ detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the proportion with extremely poor diabetes control (HbA1c ≥ 102 mmol/mol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ACC activity modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: long-term hazard of nonfatal coronary event
Endpoint domain: Mortality/survival
Primary endpoint: hazard of major cardiac event
Endpoint domain: Mortality/survival
Primary endpoint: 40 km cycling time performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐rated sexual desire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Left ventricular diastolic chamber stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recall rates for noncancer cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natriuretic peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Central venous catheter colonization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Catheter-related bloodstream infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Extent of adhesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum SHBG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum T concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MTB positivity rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inter-test agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall percent agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean IIEF-EF domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful sexual attempts (SEP3) at 15 minutes or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of late gastrointestinal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence and severity of late genitourinary toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Severity and duration of acute gastrointestinal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity and duration of acute genitourinary toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: maximal glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time-to-maximal effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total amount of glucose infused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptomatic sensitivity to beef
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BCVA score at 1 year posttreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of discontinuation reasons
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality due to tumor progression
Endpoint domain: Mortality/survival
Primary endpoint: mean total BEHAVE‐AD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean psychosis (delusions and hallucinations) subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of weight loss
Endpoint domain: Adverse events/effects
Primary endpoint: per capita FDI-inflows
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: per capita sugar from soft-drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: per capita carbonates sales volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to manic/mixed relapse
Endpoint domain: Mortality/survival
Primary endpoint: restenosis rate at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Flare area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: sustained progression of disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest troponin value measured during the first 72 hours in the ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coaction of behavior change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diastolic blood pressure readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mood state ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relief of presenting symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value for ruling out obstructive cause of neonatal cholestasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite cognitive score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton depression scale total score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale scores for back pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative bacteriuria rates
Endpoint domain: Adverse events/effects
Primary endpoint: FVII:c concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity and specificity estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MiniRQLQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in CMAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hip function (HHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative mediastinal drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Leadership ratings
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Communication skills ratings
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: End-stage renal disease (ESRD) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity and specificity of the modified PHQ-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rehabilitation efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of inhaled steroids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Femoral anteromedial bundle tunnel position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of mindfulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cAMP levels in plasma and prostate tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cGMP levels in plasma and prostate tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T/P ratio of udenafil and tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of daytime blood pressure normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IADL performances
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proximal contact variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 nonhematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 hematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative concentration of troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Significant hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: ∆TSS at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 6 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction rates in understanding the underlying disease of the knee
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in consumption of psychoactive substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of substance-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: History of atopy confirmed by positive SPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of specific IgE against house-dust mite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in migraine headache pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients pain free at 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Horizontal bone resorptive changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCP-1 expression in aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median local control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion establishing spontaneous labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean modified Bishop Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion requiring further ripening of the cervix with a Foley catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to interpret studies as definitely normal or abnormal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived need for rest imaging
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Pregnancy loss <14 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Preterm delivery 14 to <37 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Rate of low-birthweight delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: treatment engagement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Erythema at the injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Periodontal Index (PI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality in cooled and control infants
Endpoint domain: Mortality/survival
Primary endpoint: Seizures in cooled and control infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Respiratory support requirement within 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of computer median value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: whole-body fat oxidation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma concentrations of fatty acids and glycerol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma epigallocatechin gallate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Clostridium sp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in PRUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in MUP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in DSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Splenectomy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Left ventricular function (E/A ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical outcome over 6 years of service
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activated partial thromboplastin time (APTT) prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: average number of drinks consumed per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of ET-1 and Big ET-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tooth-brushing practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bottle-feeding termination practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: withdrawal response to rocuronium injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H-to-Q activation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complete loss of sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CVD risk screening time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lack of errors in calculation of CVD risk score
Endpoint domain: Adverse events/effects
Primary endpoint: End user satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for surgery
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change from surgical to nonsurgical treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: minutes of exercise per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower extremity stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of peanut allergy in siblings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Performance of serum HE4, CA125, and ROMA index in diagnosing ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of local relapse
Endpoint domain: Mortality/survival
Primary endpoint: Risk of nonbrain metastases
Endpoint domain: Mortality/survival
Primary endpoint: Risk of noncancer mortality
Endpoint domain: Mortality/survival
Primary endpoint: Probability of survival at 2.5-year post-surgery
Endpoint domain: Mortality/survival
Primary endpoint: total number of errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pancreatic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Ventilator-Associated Pneumonia (VAP) episodes per 1,000 ventilator-days
Endpoint domain: Adverse events/effects
Primary endpoint: Irritation of the oral mucosa
Endpoint domain: Adverse events/effects
Primary endpoint: Mean TASS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in beta(2)-agonist use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peroneal nerve conduction velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dynamometry improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total ZAN-BPD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes